Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 758 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Veteran Avoided The Barber For 6 Years After He Left The... February 28, 2020 Quitting Smoking Improves Survival in People with Lung Cancer September 14, 2021 Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line... May 22, 2023 Treatment Strategy for ecDNA-Driven Tumors Shows Potential December 5, 2024 Load more HOT NEWS Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies EMA Recommends Extension of Therapeutic Indications for Olaparib Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast...
